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Generalized hypersensitivity that extends into somatic areas is common in patients with irritable bowel syndrome (IBS). The
sensitized state, particularly assessed by experimental methods, is known to persist even during remissions of clinical pain. It was
hypothesized that disease-related nociceptive activity in the gut maintains a systemic-sensitized state. The present study evaluated
responses to prolonged thermal stimuli maintained at constant temperature or constant pain intensity during stimulation. The
eﬀect of topically applied rectal lidocaine on heat sensitivity was also evaluated. The question is whether silencing potential
intestinal neural activity (which may not always lead to a conscious pain experience) with lidocaine attenuates sensitization of
somatic areas. Tests were also performed where lidocaine was applied orally to control for systemic or placebo eﬀects of the drug.
The IBS subjects exhibited a greater sensitivity to somatic heat stimuli compared to controls; however, lidocaine had no discernible
eﬀect on sensitization in this sample of IBS patients, where most of the individuals did not have clinical pain on the day of
testing.
1.Introduction
Irritable bowel syndrome (IBS) is a common gastrointestinal
disorder that consists of abdominal pain that can be
associated with abnormal bowel movements [1]. The pain
often ﬂuctuates and can go into remission [2]. Since natural
variation of visceral pain occurs in IBS and other visceral
pain disorders, one method to evaluate altered pain process-
ing in IBS is to psychophysically assess responses to con-
trolled experimentally induced stimuli [3, 4]. Like other
chronic pain cohorts, IBS patients are often more sensitive
to a range of experimentally applied stimuli. For example,
distensions of the rectum with a balloon in IBS patients are
often reported as more painful and produce pain at lower
thresholds compared to individuals without IBS [5–8].
While the underlying pathophysiological mechanism(s)
are still unclear, increased sensitivity to visceral pain in IBS
patients appears to be inﬂuenced by altered processing of
aﬀerent information from the gut [7, 8]. In a recent review
by Zhou and Verne [3], several models suggest that IBS is
associated with physiological changes in gastrointestinal
tissue, which usually follow some type of injury or inﬂam-
matory insult (e.g., Salmonella infections). One proposed
pathway to enhanced pain processing includes changes to
intestinal permeability [9, 10] and low-grade inﬂammation
[11] ,w h i c hi nt u r np r o d u c e sa nu p e g u l a t i o no fp r o n o c i c e p -
tion factors (e.g., splice variants of N-methyl-D-aspartic acid
receptors, NMDA [12, 13]). Altered activity within primary
visceral aﬀerents secondarily induces changes in central pro-
cessing mechanisms (e.g., NMDA-receptor-based signaling
[14]), which manifests itself as allodynia and hyperalgesia to
stimuli within the aﬀected gastrointestinal tissue [3]. Thus,
augmented nociceptive input from gastrointestinal tissue2 Pain Research and Treatment
leads to increased visceral sensitivity and, consequently, clin-
ical symptoms.
It has been argued that changes in the neural activity
of the gut can have consequences beyond the symptomatic
region and lead to sensitization of somatic regions. Recent
studies have shown that IBS-related changes are not limited
tothegutbutexpandtosomatotopicallyremoteregionssuch
as the neck and head [15]. IBS patients are usually more
sensitive to experimental stimuli applied not only to der-
matomes corresponding to the gut but also to remote areas
that do not share the same viscersomatic convergence [5, 8,
15–19]. Functional imaging studies have supported the idea
of altered central processing of painful visceral and somatic
pain in IBS patients (for review [20]). The relationship be-
tween visceral and somatic sensitivity in IBS patients is
intriguing since it is possible that aberrant nociceptive
signals from the symptomatic visceral tissues induce somatic
hypersensitivity across the body [21]. If so, temporary inter-
ruption of nociceptive signals from the gut should allow this
hypersensitivity to decline. The idea of a regional nociceptive
focus is supported by recent studies in IBS and myofascial
pain syndrome where local anesthetics were used in an
attempt to silence a nociceptive focus that was presumed to
maintain a generalized sensitized state [22–24]. Both have
demonstrated a reduction in pain hypersensitivity in remote
areas following anesthetic intervention, which provides sup-
port for the idea that a regional nociceptive focus (i.e., gut,
muscle) plays a key role in the maintenance of hypersensitiv-
ity. However, other reports have put this view into question:
topical rectally administered lidocaine failed to reduce pain
sensitivity [25] and “trigger point” injections with saline or
simply an empty needle were no less eﬀective in reducing
pain in myofascial pain patients than lidocaine injections
[26]. The previously mentioned IBS studies also show the
impact of factors other than the pharmacological eﬀect of
lidocaine, including placebo, in driving the changes in sensi-
tivity. The disagreement between studies clearly suggests that
questions remain regarding the mechanism that maintains
widespread somatic sensitization in regional pain disorders.
Thepresentstudywasdesignedtoaddresstwoobjectives.
Theﬁrstobjectivewastoconﬁrmandextendtheobservation
that IBS patients were more sensitive to prolonged thermal
stimuli even on days when clinical pain was in remission and
that sensitization can extend to distant somatic regions (i.e.,
the upper extremities). For the ﬁrst trial, a recently described
stimulationmethodology[27,28]wasused,whichmaintains
a predetermined average pain intensity by automatically
adjusting the temperature of a Peltier-based thermode as
a function of the subject’s rating on a visual analog scale
(i.e., temperature decreased when ratings go above the set
point). In this test (the ﬁrst in the series) the subjects were
unable to identify the treatment condition based upon how
the experimental stimulus was perceived because the average
painintensityremainedthesame,regardlessofthetreatment
condition. A second test used a conventional ﬁxed stimulus
temperature protocol. It was expected that IBS patients,
when compared to normal controls, would exhibit somatic
thermal hypersensitivity in both protocols. The second
objective was to determine the eﬀects of rectal lidocaine
on somatic hypersensitivity. While designed to replicate
previous research in IBS patients [22–24], the experimental
design also controlled for placebo eﬀects including the ap-
plication of lidocaine in the oral cavity, which is not aﬀected
by the symptoms of IBS. It was expected that topical rectal
but not oral lidocaine would lead to a reduction in somatic
sensitization.
2. Methods
2.1. Subjects. Participants of the study were recruited from
diverse social settings and had no close contact with each
other. Recruitment and study procedures were approved by
the University of Florida Institutional Review Board. Written
informed consent was obtained from all participants. The
criteria for membership in the control group required (a) no
signiﬁcant spontaneous pain anywhere in the body, (b) no
ongoing pharmacotherapy with narcotics or antidepressants,
(c) no disease or condition that might signiﬁcantly aﬀect
pain perception or unduly increase risk of injury (e.g., neu-
rological disorders, serious psychiatric disorders, diabetes,
hypertension, serious cardiovascular disorders, pregnancy,
and chronic pain diseases such as ﬁbromyalgia syndrome),
(d) no prior complications or allergies with the local anes-
thetic lidocaine. The criteria for the disease group required
a diagnosis of ongoing IBS based upon the Rome II criteria
[29], supplemented by additional criteria: absence of other
diseases (including other chronic pain diseases), risk factors,
and ongoing drug treatments, as described for the control
group. Rome II criteria [24] are twelve weeks or more in
the past 12 months of abdominal discomfort or pain that
has two out of three features: relieved with defecation; onset
associated with a change in frequency of stool; and onset
associated with a change in form of stool. Patients with a
history of widespread pain (e.g., individuals with ﬁbromyal-
giasyndrome)wereexcludedfromthestudy.Initialscreening
consisted of blood pressure measurement, completion of a
health questionnaire, and a clinical diagnosis for IBS patients
by a physician. Subject recruitment did not control for men-
strual phase or contraceptives.
2.2. Testing Methodology
2.2.1. Questionnaires. The subjects were given three psycho-
logical assessment forms during the training session (session
1) to evaluate overall levels of depression (Beck Depression
Inventory [30]), anxiety (State Anxiety Trait Inventory [31]),
and somatization (Symptom Checklist [32]).
2.2.2. Pain Measurement. Spontaneous clinical pain and
experimental pain (induced by thermode) were measured
with an electronic version of a visual analog scale [33]a s
mentioned previously [17, 27]. The electronic visual analog
scale(eVAS)consistedofalow-frictionslidingpotentiometer
of100mmtravel.Theleftendpointofthescalewasidentiﬁed
as “no pain,” while the right endpoint was labeled as “in-
tolerably intense pain.” The position of the slider was
electronically converted into a pain rating between 0 andPain Research and Treatment 3
100%. The slider automatically returned to the left “no pain”
position when so required by the protocol.
2.2.3. Thermal Nociceptive Stimulation. Thermal stimuli
were administered with a ﬂat copper contact thermode
(25 × 25mm). The thermode was electronically held at the
desired temperature by a Peltier thermoelectric device and
was brought into light skin contact of reproducible force by
solenoid activation.
2.3. Testing Protocol. Test sessions consisted of daily testing
sessions across seven nonconsecutive days (Table 1). Subjects
were scheduled irrespective of whether or not IBS patients
had an acute exacerbation of symptoms on the day of
testing. Following assessment of clinical pain (Section 2.3.1),
pain sensitivity was measured with two diﬀerent testing
protocols. The ﬁrst protocol (pain intensity clamping) used
a prolonged thermal contact with automatically adjusted
temperature that maintained a predetermined pain intensity
rating (Section 2.3.2). The second protocol administered
series of thermal pulses of ﬁxed temperature and measured
the pain intensity elicited by these pulses (Section 2.3.3).
Subjects were not informed about the order and expected
eﬀects of the treatments in order to minimize rating bias.
During three of the seven daily test sessions (sessions 2, 5,
and 7), pain sensitivity was assessed in the absence of any
lidocaine or vehicle treatment. An overview of the drug and
placebo schedule is shown in Table 1. The double-placebo
treatment, which consisted of both an oral and rectal
administration of KY Jelly without an anesthetic, was always
ﬁrst (session 3). Lidocaine (Section 2.4) was applied rectally
(session4)andorally(session6).Onsessionswhenlidocaine
was used rectally, KY Jelly was applied orally and vice versa.
Lidocaine sessions were always followed by a testing session
without lidocaine application to monitor for potential
residual eﬀects of the anesthetic that might contaminate the
subsequent lidocaine session (sessions 5 and 7).
2.3.1. Ratings of Clinical Pain. All participants began each
daily session by rating their spontaneous pain of the upper
(head, neck, shoulder, upper back, arms, and hands) and
lower (low back, bowel, legs, and feet) parts of the body on
the eVAS. The subjects were then asked to rate the unpleas-
antness of the single most intense clinical pain. Several of
thepatientsreported spontaneous pain ordiscomfortduring
some of the sessions. For the control group, all these ratings
were required to be below 5% (on the 0–100% eVAS scale).
2.3.2. Prolonged Painful Stimulus at a Fixed Pain Intensity
Rating (Trial 1). Pain testing began with a prolonged
thermal stimulus to the thenar eminence of the right hand
(Table 2). As reported previously [27, 28], the stimulus was
controlled as a function of the pain intensity rating and
maintained 25% average pain intensity for 120 seconds by
modulatingthethermodetemperature(dependentvariable).
Prolonged stimulation consisted of two phases: induction
and maintenance phase. At the beginning of stimulation, the
thermode temperature was 34◦C, which did not elicit pain
Table 1: Testing and treatment conditions over 7 nonconsecutive
sessions. The seven sessions were spread out over two weeks,
typically with 4 sessions during the ﬁrst and 3 sessions during the
second week. Following a training session, baseline sessions were
assessed on sessions 2, 5, and 7. The ﬁfth and seventh sessions
were used to assess carryover eﬀects of the treatment conditions.
Treatment sessions were carried out on sessions 3, 4, and 6,
which included a combination of rectally and orally administered
anesthetic (i.e., lidocaine) and placebo. The order of anesthetic and
placebo were not random. The anesthetic was administered either
rectally(session4)ororally(session6)whiletheothersitewasgiven
a placebo (i.e., oral placebo on session 4, rectal placebo on session
6).
Testing Conditions Treatment Conditions
Session Rectal Oral
(1) Training No treatment No treatment
(2) Baseline 1 No treatment No treatment
(3) Treatment 1 Placebo (PL) Placebo (PL)
(4) Treatment 2 Lidocaine (LID) Placebo (PL)
(5) Baseline 2 No treatment No treatment
(6) Treatment 3 Placebo (PL) Lidocaine (LID)
(7) Baseline 3 No treatment No treatment
in any of the subjects. Then, during the induction phase, the
temperature was slowly stepped up in 0.6◦C/sec increments
until a pain intensity of 10% was reached. At this point, the
temperature continued to increase in 0.3◦C increments. The
induction phase ended and the maintenance phase began
when the pain intensity rating ﬁrst reached the set point
of 25% on the eVAS. Temperature and eVAS rating were
sampled once per second.
2.3.3. Prolonged Painful Stimulus at Fixed Temperature (Trial
2). The subject was repositioned to test the left thenar
eminence. Pain sensitivity was assessed with a continuous
thermal stimulus at a standardized temperature (Table 2).
The thermode was held in contact with the skin while
the temperature was ramped from 34 to 47deg C (rate of
1.5deg/sec) and then held at this temperature for 30sec.
PainintensitywascontinuouslyratedontheeVASduringthe
stimulus.
2.4. Lidocaine. For the lidocaine conditions, a jelly contain-
ing 2% lidocaine (150–300mg per application; AstraZeneca)
orasimilarvolumeofplacebo(KYJelly)wasdigitallyapplied
r e c t a l l ya n do r a l l yi na l lI B Sa n dc o n t r o ls u b j e c t sp r i o rt o
testing on three of the seven daily testing sessions (Table 2).
Pain testing began within 15 minutes after administration,
when the lidocaine eﬀect was expected to peak [34].
2.5. Data Analysis. One-way ANOVA was used to test for
group diﬀerences on measures of anxiety, depression, and
somatization. Further relationships between psychological
variablesandpsychophysicalpainmeasuresweredetermined
with Pearson correlations. Repeated measures analysis of
variance (ANOVA) was used for statistical analysis with age4 Pain Research and Treatment
Table 2: Order of experimental trials during each testing session. All trials were conducted during each session.
Trial Stimulus Induced Pain Testing site Parameters
1 Prolonged thermal stimulus at ﬁxed pain intensity Right thenar Temperature adjusted to maintain a pain rating ∼25%
(eVAS)
2 Prolonged thermal stimulus at ﬁxed temperature Left thenar Pain ratings to a 30sec pulse at 47◦C
entered as a covariate. Bartlett’s test of sphericity of the
residual covariance matrix was used to test the sphericity
assumption. Greenhouse-Geisser adjustments were made
where appropriate. For trial 1, the factors were Group (IBS
patient, healthy controls) and Treatment (average baseline;
double placebo (session 3), rectal lidocaine (session 4), oral
lidocaine(session6)).One-wayANOVAwasusedtoevaluate
diﬀerences among the three baseline sessions (i.e., sessions 2,
5,and7),whichwereaveraged.Thedependentvariableswere
thermode temperature when pain rating ﬁrst reached 10%,
temperature at the end of the induction phase (i.e., when
pain rating ﬁrst reached set point of 25%), and the average
temperature needed to maintain the set pain intensity
throughout the window from 51–60sec of the prolonged
ﬁxed painful stimulus. For trial 2, the factors for the ﬁxed
prolonged painful stimulus were Group and Treatment. The
dependent variables were the second of the trial where the
eVAS rating ﬁrst reached 10%, peak pain rating during the
trial, and the average pain rating across the trial.
3. Results
3.1. Clinical Characteristics of Subjects. Characteristics of the
participants in the current study are presented in Table 3.A n
equal number of diarrhea-predominant female IBS patients
(n = 11) between the ages of 18 and 52 years old and healthy
controls (n = 11) between the ages of 20–54 completed the
study. All subjects were right-handed.
3.2. Baseline Assessments of Psychological Proﬁle. Scores of
Symptom Checklist (i.e., somatization measure) were higher
inIBSpatientscomparedtohealthycontrols(Control:96.8±
17.9; IBS: 102.7 ± 18.1; F (1, 21) = 5.129, P = 0.03).
The groups did not diﬀer on degree of depression (Control:
4.7 ± 3.6; IBS: 7.6 ± 6.4; F (1, 21) = 0.615, P>0.10) or
anxiety (Control: 29.9 ± 4.7; IBS: 38.6 ± 12.3; F (1, 21) =
0.615, P>0.10). The psychological scores did not correlate
with any psychophysical pain measures or treatment eﬀects
(All P>0.10).
3.3. Group Diﬀerences to a Prolonged Painful Stimulus at
a Fixed Pain Intensity Rating (Trial 1). Diﬀerences across
the 3 control sessions were tested for the three dependent
variables: temperature of the thermode at an initial pain
intensity rating of 10% and 25% (i.e., induction phase) and
the average temperature to maintain a pain intensity rating
of 25% (i.e., maintenance phase). The results of repeated
measure ANOVA (Group × Day × Measure) indicated that
there were no diﬀerences across the 3 control sessions (All
P>0.10). Consequently, data for the 3 control sessions were
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Figure 1:Continuousthermalstimulusappliedtothenareminence
ofrighthandofIBS(openbars)andcontrol(graybars)participants
during baseline sessions. Thermode temperatures during induction
phase at the time when pain intensity ﬁrst reached 10% and 25%
were lower for the IBS group compared to controls. The average
temperature needed to maintain pain intensity at 25% was also
lower for the IBS group.
collapsed for all further analysis (nonsigniﬁcant main eﬀect
of session or interaction term involving session). However,
diﬀerences were observed between IBS and control groups
regarding measures during the induction and maintenance
phase of thermal stimulation. In Figure 1, IBS patients as a
group, when compared to their healthy counterparts, were
signiﬁcantly more sensitive to thermal nociceptive stimula-
tion(i.e.,thetemperaturesneededforelicitinganygivenpain
intensity level were lower).
Table 4 shows the average temperatures during the in-
duction and maintenance phases under diﬀerent treatment
conditions with lidocaine and placebo. Under all treatment
conditions, a similar pattern was observed in which the IBS
group needed lower temperatures to elicit the deﬁned
amount pain intensity during both phases. The data further
suggest that the IBS and control groups were aﬀected equally
by the treatments, and that the eﬀect of rectal and oral lido-
caine application did not diﬀer to a statistically signiﬁcant
degree. This ﬁnding does not support the notion that gener-
alized sensitization of IBS patients in somatic areas distant
from the gut (i.e., the hands) is primarily maintained by a
localizednociceptivefocus.Fortheinitialpainratingof10%,
repeated measure ANOVA indicated a signiﬁcant main eﬀect
of group (F (1,20) = 6.579, P = 0.018). The main eﬀect
of treatment (F (3,18) = 1.238, P>0.05) and treatment ×
group (F(3,18) = 0.649, P>0.05) interactions werePain Research and Treatment 5
Table 3: Average clinical pain reports (±SD) across the treatment conditions in IBS subjects. The majority of IBS patients did report clinical
pain at one time or another throughout the time period of their involvement in the study, but not always on the days of testing. None of the
control subjects had any pain, and therefore control subjects are not listed in the table. No correlation was found between lidocaine eﬀect
and clinical symptoms during or between sessions in the lower or upper part of the body (All P>0.10).
Baseline
(Session 1)
Double placebo
(Session 3)
Rectal lidocaine
(Session 4)
Oral lidocaine
(Session 6)
Upper body intensity (0–100%) 22.0 (7.1) 22.0 (7.1) 19.0† 41.5 (13.4)
Lower body intensity (0–100%) 24.7 (14.2) 24.7 (14.2) 68.0† 23 (0.0)
Unpleasantness of clinical pain (0–100%) 37.3 (17.82) 37.3 (17.82) 82.0† 48.0 (2.83)
Number subjects reporting pain (%) 4 (36%) 4 (36%) 1 (9%) 2 (18%)
Abbreviations: †, ratings for single subject.
Table 4: Average thermode temperatures (±SD) of prolonged painful stimulus at a ﬁxed intensity rating between IBS and control
participants (Trial 1). The baseline session represents data collapsed across sessions 2, 5, and 7. Participants rated a continuous thermal
stimulus to induce 10% and 25% pain intensities during the induction phase and sustain 25% pain intensity during the maintenance phase
for the various testing sessions with (rectal: rectal lidocaine + oral placebo;o r a l :rectal placebo + oral lidocaine) and without (placebo: rectal
placebo + oral placebo) application of lidocaine.
IBS CONTROL
Baseline Placebo Rectal Oral Baseline Placebo Rectal Oral
Induction
10% (◦C) 43.6 (2.4) 44.2 (2.1) 43.9 (2.7) 44.7 (2.7) 45.8 (1.9) 46.5 (2.2) 46.3 (1.8) 46.6 (1.2)
25% (◦C) 44.2 (2.4) 44.1 (2.4) 46.3 (1.8) 44.2 (2.8) 46.6 (1.7) 46.6 (2.5) 46.4 (1.9) 46.8 (1.4)
Maintenance
25% (◦C) 45.5 (1.8) 44.8 (2.3) 45.8 (1.7) 45.8 (2.0) 47.3 (1.7) 47.0 (1.9) 47.3 (2.2) 47.7 (1.7)
not signiﬁcant. For the initial pain rating at 25%, repeated
measure ANOVA indicated a signiﬁcant main eﬀect of group
(F (1,20) = 6.923, P = 0.016). However, the main eﬀect of
treatment (F (3,18) = 0.480, P>0.05) and treatment ×
group (F (3,18) = 1.556, P>0.05) interaction were not sig-
nificant. Continuing this trend, the average thermode tem-
perature to maintain a rating of 25% was lower in the IBS
group. A repeated measure ANOVA indicated a signiﬁcant
main eﬀect of group (F (1,20) = 5.731, P = 0.027), but the
main eﬀect of treatment (F (3,18) = 0.007, P>0.05) and
treatment × group (F (3,18) = 0.664, P>0.05) interaction
were not signiﬁcant.
3.4.GroupDiﬀerencestoaProlongedPainfulStimulusatFixed
Temperature (Trial 2). Responses to a 30sec 47◦Cs t i m u l u s
are presented in Table 5. For the control sessions (session 2,
5, and 7), diﬀerences across the 3 control sessions were tested
for the three dependent variables: time to pain intensity of
10%, peak pain intensity, and average pain intensity. The
results of repeated measure ANOVA (Group × Session ×
Measure)indicatedthattherewerenodiﬀerencesacrossthe3
control sessions, consequently, data for the 3 control sessions
( s e s s i o n s2 ,5 ,a n d7i nTable 1) were collapsed for all further
analysis.
As reported in Table 4, in Trial 1, the IBS group reached a
painintensityratingof10%inasigniﬁcantlyshorteramount
oftimeandtheirpainintensityratingswerehighercompared
to controls. However, these measures were not signiﬁcantly
aﬀected by the treatment conditions. For the time to 10%, a
repeated measure ANOVA indicated a signiﬁcant main eﬀect
of group (F (1,20) = 5.380, P = 0.031). The main eﬀect
of treatment (F (3,18) = 0.604, P>0.05) and treatment ×
group (F (3,18) = 0.1383, P>0.05) interaction were not
signiﬁcant. In addition, a repeated measure ANOVA for peak
painintensityindicatedanonsigniﬁcantmaineﬀectofgroup
(F (1,20) = 3.675, P = 0.070). The main eﬀects of treatment
(F (3,60) = 3.521, P = 0.036) and treatment × group (F
(3,18) = 1.109, P>0.05) interaction were signiﬁcant. Finally,
a repeated measure ANOVA for the average pain intensity
indicated a signiﬁcant main eﬀectof group (F (1,20) = 4.933,
P = 0.038). The main eﬀects of treatment (F (3,60) = 1.260,
P>0.05)andtreatment ×group(F (3,18) =1.579,P>0.05)
interaction were not signiﬁcant.
4. Discussion
The goal of this study was to verify the existence of somatic
hypersensitivity on glabrous skin of the hands in IBS patients
and determine the interaction between potential intestinal
neural activity and somatic sensitization. The current study
conﬁrmed the presence of somatic hypersensitivity, even
during remissions of clinical pain and in a region distant
from the segmental level of the gut (i.e., the hands). The
sensitization was demonstrated with both protocols used
in this study, that is, with the method that measured the
temperature required to maintain a predetermined level of
pain and the method that used a ﬁxed stimulus temperature
and measured the pain intensity elicited by it. The degree
of somatic sensitization of the hands was not attenuated
by rectal lidocaine, nor was it aﬀected by topical lidocaine
applied at the control location, the oral cavity.6 Pain Research and Treatment
Table 5: Average time to a pain rating of “10%” and eVAS ratings (±SD) of a 30 second pulse of 47.0◦C on the left thenar (Trial 2). The
baseline session represents data collapsed across sessions 2, 5, and 7. Pain intensity was continuously rated on a 0 to 100 scale. Time to obtain
a rating of “10%” is measured in seconds. Continuous ratings of thermal pain were analyzed to determine peak (highest pain rating during
the trial) and average (i.e., average amount of pain reported during the trial) pain.
IBS CONTROL
Baseline Placebo Rectal Oral Baseline Placebo Rectal Oral
Time to 10% (sec) 4.7 (1.6) 4.5 (1.4) 4.2 (1.3) 4.6 (1.0) 7.8 (4.0) 6.1 (3.2) 6.4 (2.4) 6.4 (3.6)
Peak Pain 69.2 (21.4) 65.9 (32.3) 71.1 (24.7) 63.4 (22.9) 46.1 (20.7) 46.9 (20.0) 50.4 (23.9) 51.4 (23.6)
Average pain 41.5 (14.0) 44.6 (27.7) 44.3 (17.8) 39.0 (15.6) 24.3 (13.4) 22.7 (17.1) 28.3 (17.8) 29.5 (17.2)
Previous studies of our laboratory [17, 28, 35] and others
[5, 8, 15, 16, 18, 19, 36] have supported the idea that IBS
patients are more sensitive than healthy controls to a range
of laboratory stimuli, including to heat. The data of the
present study are in agreement with these earlier ﬁndings as
the temperature needed to elicit a moderate pain intensity
level of 25 on a scale of 0–100 tended to be approximately
2 degrees lower for the IBS group compared to the healthy
control group. Likewise, IBS patients, when compared to
healthycontrols,ratedthepainintensityelicitedbyathermal
pulse of given temperature as more painful.
A continuous barrage of tonic impulses emanating from
symptomatic viscera and viscerosomatic convergence had
been proposed as the basis for the induction and mainte-
nance of sensitization to regions beyond the gut [5, 8, 15,
16, 18, 19, 36]. Some earlier studies [8, 15, 18, 23] that used
thermal water immersion stimuli and threshold/tolerance
measures found a declining sensitization gradient from the
symptomatic segments to more proximal segments. Other
experiments that used focal thermal cutaneous stimuli with
a deﬁned contact area to the cheek, forearm, and calf con-
ﬁrmed the existence of widespread cutaneous sensitization
but failed to demonstrate a gradient eﬀect [17]. Spinal
sensitization of IBS patients was also demonstrated in a
model of NMDA receptor-dependent temporal summation
[36]. Most studies are in agreement in one ﬁnding: the
central nervous system in IBS patients is altered beyond the
symptomatic region of the gut.
The application of rectal topical local anesthetics oﬀers a
pharmacological tool to evaluate the contribution of neural
activity within the gut to changes in neural processing that
extend into distant somatic areas. This basic concept has
already found support in experiments where pharmacolog-
ical blockade of nociceptive input normalized clinical and
stimulus-induced pain [37–39].
Our results are in agreement with two studies that
examined visceral sensitivity following rectal lidocaine in
normal subjects [25, 40] but may compliment earlier studies
that were conducted in IBS patients [23, 24]. A number
of factors and mechanisms need to be considered when
analyzing the diﬀerence in results between studies.
(1) Placebo Eﬀect. Unlike the mentioned earlier studies,
the present investigation included tests where topical
lidocaine was applied orally to control for placebo
and systemic eﬀects. The subject was kept in the
dark as to whether the oral or rectal application
represented the “active” treatment. This was impor-
tant because a subject that can identify lidocaine by
its numbing eﬀect in the area of application (i.e., anal
region) may become biased and develop an uncon-
trolled placebo eﬀect. Furthermore, the present study
took into account the possibility that subjects could
develop a reinforced placebo eﬀect based upon how
they perceive the experimental stimulus early on in
the experimental series. If subjects realize that the
stimuli appear to be less painful under a certain
test condition, they may be biased later on in the
experiment and perceive subsequent tests even less
painful. The ﬁrst test in the present study always used
a pain intensity clamping method where the elicited
pain intensity level was the same regardless of test
condition.Thetemperaturethatwasrequiredtoelicit
that predetermined pain level (and that served as the
response variable) was unknown to the subject. In
thepresentstudy,alidocaineeﬀectonpainsensitivity
was not detected and therefore concerns regarding a
positive placebo eﬀect are moot.
(2) Systemic Eﬀect. An earlier study [23]r e p o r t e dt oh a v e
measured lidocaine blood levels to rule out systemic
eﬀects. It is well accepted that systemic lidocaine can
lead to signiﬁcant reductions in pain at very low
blood levels (i.e., as low as 1 microgram/milliliter
concentration) [41–44]. Systemic lidocaine is known
to have an attenuating eﬀe c to np a i nr e s p o n s e si n
neuropathic conditions of human and animal mod-
els,aswellasinhumanpostoperativeabdominalpain
[45,46].Interestingly,intravenouslidocainehasbeen
shown to reduce secondary mechanical hyperalge-
sia without aﬀecting sensitivity thresholds [47]. It,
therefore, cannot be ruled out that levels of lidocaine
below the detection threshold of common blood
assays might have an attenuating eﬀect on pain. This
raises the question whether the blood assay has been
sensitive enough to conclusively rule out systemic
eﬀects of lidocaine on pain processing. Considering
the fact that it may be diﬃcult to reliably rule out any
potential systemic lidocaine eﬀects with blood tests,
the present study’s approach was to control for sys-
temic eﬀects with a control experiment where the
drug was applied in a mucosa lined region distant
from the gut (i.e., the oral cavity). A systemic
lidocaine eﬀect should have reduced pain sensitivityPain Research and Treatment 7
regardless whether lidocaine was administered rec-
tally or intraorally. Systemic eﬀects do not appear to
be an issue in the present study because no lidocaine
eﬀect was detected in either location of application.
(3) Method and Location of Stimulation. Somatic sensi-
tization of Verne’s et al. [23] and the present study
wasmeasuredwithdiﬀerentstimuliandinadiﬀerent
location.Verneetal.appliedawaterimmersionstim-
ulus to the foot, while the present study used a focal
contact stimulus to the glabrous skin of the hand.
One could argue that the lidocaine is able to aﬀect
somatic sensitization in the same segmental region as
the gut (the foot) but be ineﬀective in regions that
are segmentally distant, and therefore, enhanced pain
sensitivity in IBS patients may rely on mechanisms
other than “vicious cycle” type sensitization by vis-
cerosomatic convergence.
(4) Patient Sample. In the study by Verne and colleagues,
the intensity of clinical (spontaneous) pain was at
least 30 (on a scale from 0–100) during the exper-
imental session while most subjects in the present
studyhadnospontaneouspainonthedaysoftesting.
The present study eﬀectively standardized the subject
groups based upon their somatic pain sensitivity (all
subjects in the IBS group were sensitized on the
hand). Additional standardization based upon their
clinical pain on the days of testing would have
been advantageous. Standardizing subjects of the IBS
group based upon their clinical pain would only be
useful if it is assured that they have clinical pain
of approximately the same intensity on each day of
testing. This is more diﬃcult to accomplish in a study
with many sessions due to extensive controls for pla-
cebo and systemic eﬀects.
Diﬀerences in symptom severity on the days of testing
are a likely explanation for the diﬀerence in results between
Verne’s et al. study [23] and the present results. The hy-
pothesis that rectal lidocaine can only reduce the portion of
sensitization that is maintained by intestinal neural activity
that is strong enough to result in a conscious pain experience
needs to be considered. The portion of somatic sensitization
thatremainsduringremissionsofclinicalpainmaynolonger
be reversible by the drug. This notion is consistent with a
report [37] where neuropathic patients with greater pain
severity exhibited greater analgesic response. Furthermore,
in a followup to the aforementioned study, it was found that
thequalitativeexperiencesrelatedtoclinicalpaindetermined
the eﬃcacy of lidocaine to reduce pain [39]. A factor analysis
of pain qualities, which were collected from the short-form
McGill Pain Questionnaire, revealed that a subgroup of
patients with higher levels of “heavy” pain qualities expe-
rienced greater pain reduction following intravenous lido-
caine.Inthislight,itmaybeunderstandablewhyinourstudy
somatic sensitization was unresponsive to rectal lidocaine:
most subjects’ clinical pain was in remission on the day of
testing. It is possible that somatic pain sensitization is not
mainly induced or maintained by a nociceptive focus in
the gut through a “vicious cycle” mechanism but a result
of other factors (some of which may predate the clinical
onset of IBS) including a deﬁcit in tonic inhibition or
descending facilitation. Events that occurred much earlier in
life, such as stress, inﬂammation or dysfunctional endocrine
functioning [48–56], could have induced plastic changes in
the pain processing system and led to permanent widespread
hyperalgesia. Indeed, symptom-free control subjects are
occasionally encountered that are as sensitive in thermal
pain tests as the most sensitive IBS patients [16]. It will be
important in future studies to collect a thorough disease
and trauma history from birth to the present from these
individuals because it may provide clues regarding the cause
of their sensitization. Once a widespread sensitized state is
established, it will take only a small local insult to start a
regional (e.g., IBS, MPS) or generalized (FMS) pain condi-
tion. In other words, preexisting changes in the pain proc-
essing system may have rendered these patients pain prone
longbeforethespontaneoussymptomsthatdeﬁnethesepain
diseases emerged. This argument ﬁnds support in animal
models [57]. It has been possible to induce lifelong visceral
and somatic hyperalgesia in rats with visceral insults early
in life [58]. In these models, sensitization appears to persist
even after visceral pathology associated with the insult is no
longer visible. The issue could be put to rest by conducting
a longitudinal study on large samples of symptom-free sub-
jects.Thepredispositiontheorywouldbesupportedifhyper-
algesia can be demonstrated in a subpopulation of healthy
subjects and that these individuals have a higher likelihood
of developing pain conditions later in life [59]. The most
clinically pressing question would then be how sensitization
from an early life insult can be prevented from becoming
permanent.
In conclusion, our results conﬁrm that IBS patients are
somatically sensitized even in regions that are segmentally
distant from the gut. Earlier ﬁndings that somatic sensitiza-
tion can be reduced by the application of rectal lidocaine are
not conﬁrmed by the present study. The most likely explana-
tions for the diﬀerent ﬁnding are that the eﬀect of lidocaine
(a) may not extend to somatic areas that are segmentally
distant from the gut or (b) to sensitization that persists even
during periods of symptom remission. Therefore, it can
be argued that somatic sensitization that is maintained by
nociceptive signals in the gut may be sensitive to lidocaine
while another type of sensitization exists that is stable and
no longer reversible by lidocaine. The present study points
toward the existence of this latter mechanism without allow-
ing detailed insights into its function.
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